Last reviewed · How we verify
moderate-to-severe atopic dermatitis
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. - Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Abrocitinib Suspension F2 · Pfizer
- Adbry · Leo Pharma As
Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis. - Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 450 mg SC Q4W · Pfizer
- Ebglyss · Eli Lilly And Co
Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin. - Ebglyss · Eli Lilly And Co
Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- moderate-to-severe atopic dermatitis patent landscape — cliff calendar, originator estates, attackable patents
- moderate-to-severe atopic dermatitis treatment landscape brief
- moderate-to-severe atopic dermatitis treatment updates RSS
Frequently asked questions about moderate-to-severe atopic dermatitis
What drugs treat moderate-to-severe atopic dermatitis?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Abrocitinib Suspension F2, Adbry, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W, Ebglyss.
What is the treatment for moderate-to-severe atopic dermatitis?
Standard treatment for moderate-to-severe atopic dermatitis includes Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Abrocitinib Suspension F2, Adbry. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: moderate-to-severe atopic dermatitis patent cliff · moderate-to-severe atopic dermatitis CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Treatment: Induction- PF-06480605 150 mg SC Q4W · Pfizer
- Treatment: Abrocitinib Suspension F2 · Pfizer
- Treatment: Adbry · Leo Pharma As
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing